Treatment of Sydenham’s Chorea

  • Francisco Cardoso
Part of the Current Clinical Neurology book series (CCNEU)


Sydenham’s chorea, an autoimmune movement disorder caused by Streptococcus-induced antibodies that cross-react with basal ganglia antigens, is the most common cause of acute chorea in children worldwide. The clinical features include chorea and other motor findings as well as non-motor features such as obsessions, compulsions, and hyperactivity. The management is based on control of chorea and prophylaxis of new streptococcal infections. Although there are no evidence-based recommendations, valproic acid and other anticonvulsant agents are the first-line antichoreic agents. Risperidone and other neuroleptics are used for patients who fail to improve with anticonvulsant agents. If patients do not respond to the first- and second-line agents, they should be treated with corticosteroids. Prophylaxis with antibiotics is warranted to prevent recurrence of rheumatic fever.


Sydenham’s chorea Rheumatic chorea Rheumatic fever Chorea Chorea paralytica Carditis Arthritis Neuroleptics Corticosteroids Prophylaxis 

Suggested Reading

  1. Beato R, Maia DP, Teixeira AL Jr, Cardoso F. Executive functioning in adult patients with Sydenham’s chorea. Mov Disord. 2010;25:853–7.CrossRefGoogle Scholar
  2. Cardoso F, Silva CE, Mota CC. Sydenham’s chorea in 50 consecutive patients with rheumatic fever. Mov Disord. 1997;12:701–3.CrossRefGoogle Scholar
  3. Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham’s chorea. Mov Disord. 1999;14:805–7.CrossRefGoogle Scholar
  4. Cardoso F, Maia D, Cunningham MC, Valenca G. Treatment of Sydenham chorea with corticosteroids. Mov Disord. 2003;18:1374–7.CrossRefGoogle Scholar
  5. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol. 2006;5:589–602.CrossRefGoogle Scholar
  6. Church AJ, Cardoso F, Dale RC, et al. Anti-basal ganglia antibodies in acute and persistent Sydenham’s chorea. Neurology. 2002;59:227–31.CrossRefGoogle Scholar
  7. Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf). 2016;216:90–100.CrossRefGoogle Scholar
  8. Dale RC, Singh H, Troedson C, Pillai S, Gaikiwari S, Kozlowska K. A prospective study of acute movement disorders in children. Dev Med Child Neurol. 2010;52:739–48.CrossRefGoogle Scholar
  9. Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24:73–6.CrossRefGoogle Scholar
  10. Harrison NA, Church A, Nisbet A, Rudge P, Giovannoni G. Late recurrences of Sydenham’s chorea are not associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry. 2004;75:1478–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Francisco Cardoso
    • 1
  1. 1.Movement Disorders Clinic, Neurology Service, Department of Internal Medicine, UFMGBelo HorizonteBrazil

Personalised recommendations